{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"This is the only treatment arm in this study. Up to 8 participants will receive a single oral dose of 200 mg containing approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib, 30 minutes after starting a standard high-fat breakfast.\n\nBemcentinib: Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.","id":"EG000","otherNumAffected":3,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Single Dose Cohort - 200 mg Containing Approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":2}],"term":"Headache"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Vessel Puncture Site Bruise","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Bruising Right Antecubital Fossa (Venepuncture Related)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Loose Stool"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Vessel Puncture Site Bruise","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Bruising to Left Antecubital Fossa (Venepuncture Related)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"COVID-19"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Sore Throat"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Night Sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (25.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Night Sweats"}],"timeFrame":"Adverse events were reported through ad hoc reporting from the participants from the point of signature of informed consent through to study completion (up to 5 weeks)."}